UNSPSC 51432900: Antihypertensive organophosphorus compounds

Antihypertensive drugs made from organic compounds that contain phosphorus as an integral part of the molecule.

UNSPSC 51432900 Antihypertensive organophosphorus compounds is a Class code that encompasses prescription and over-the-counter medications used in emergency response and state health programs, though recent state and local solicitations under this code show a broader pharmaceutical procurement pattern. State and local government buyers under this code include city fire and rescue departments procuring advanced life support medications for emergency medical services, state health and human services agencies developing pharmacy benefit programs, and cooperative purchasing alliances sourcing generic pharmaceuticals and OTC products across multiple participating jurisdictions. The scope of work includes direct supply of specific medication line items to emergency response and healthcare facilities, direct-to-manufacturer prescription program development to improve fulfillment efficiency and cost management, and multi-source generic pharmaceutical supply agreements distributed through authorized wholesalers to state and local government facilities.

Recent activity spans Florida, Texas, and the upper Midwest through cooperative mechanisms. The City of Tampa's Purchasing Department issued IFB 26P00188 in April 2026 for Advanced Life Support Medications—specifically Labetalol HCl, Epinephrine, Adenosine, and Diltiazem vials—for Tampa Fire Rescue in Hillsborough County, with a response deadline of April 8, 2026 and an estimated contract value of $40,000. The Texas Health and Human Services Commission posted RFI HHS0017013 in March 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, with responses due April 3, 2026. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon, with responses due March 26, 2026 and contract effectiveness scheduled for July 1, 2026. All vendors must demonstrate compliance with current Good Manufacturing Practices, Drug Supply Chain Security Act requirements, and FDA standards, with products requiring expiration dates of at least one year from manufacture and minimum six-month shelf life.